H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals to CHF 28 from CHF 24 and keeps a Buy rating on the shares after the FDA approved Agamree the treatment of Duchenne muscular dystrophy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>